» Articles » PMID: 37434129

Interferon-γ Regulates Immunosuppression in Septic Mice by Promoting the Warburg Effect Through the PI3K/AKT/mTOR Pathway

Overview
Journal Mol Med
Publisher Biomed Central
Date 2023 Jul 11
PMID 37434129
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The main cause of high mortality from sepsis is that immunosuppression leads to life-threatening organ dysfunction, and reversing immunosuppression is key to sepsis treatment. Interferon γ (IFNγ) is a potential therapy for immunosuppression of sepsis, promoting glycolysis to restore metabolic defects in monocytes, but the mechanism of treatment is unclear.

Methods: To explore the immunotherapeutic mechanism of IFNγ, this study linked the Warburg effect (aerobic glycolysis) to immunotherapy for sepsis and used cecal ligation perforation (CLP) and lipopolysaccharide (LPS) to stimulate dendritic cells (DC) to establish in vivo and in vitro sepsis models, Warburg effect inhibitors (2-DG) and PI3K pathway inhibitors (LY294002) were used to explore the mechanism by which IFNγ regulates immunosuppression in mice with sepsis through the Warburg effect.

Results: IFNγ markedly inhibited the reduction in cytokine secretion from lipopolysaccharide (LPS)-stimulated splenocytes. IFNγ-treated mice had significantly increased the percentages of positive costimulatory receptor CD86 on Dendritic cells expressing and expression of splenic HLA-DR. IFNγ markedly reduced DC-cell apoptosis by upregulating the expression of Bcl-2 and downregulating the expression of Bax. CLP-induced formation of regulatory T cells in the spleen was abolished in IFNγ -treated mice. IFNγ treatment reduced the expression of autophagosomes in DC cells. IFNγ significant reduce the expression of Warburg effector-related proteins PDH, LDH, Glut1, and Glut4, and promote glucose consumption, lactic acid, and intracellular ATP production. After the use of 2-DG to suppress the Warburg effect, the therapeutic effect of IFNγ was suppressed, demonstrating that IFNγ reverses immunosuppression by promoting the Warburg effect. Moreover, IFNγ increased the expression of phosphoinositide 3-kinases (PI3K), protein kinase B (Akt), rapamycin target protein (mTOR), hypoxia-inducible factor-1 (HIF-1α), pyruvate dehydrogenase kinase (PDK1) protein, the use of 2-DG and LY294002 can inhibit the expression of the above proteins, LY294002 also inhibits the therapeutic effect of IFNγ.

Conclusions: It was finally proved that IFNγ promoted the Warburg effect through the PI3K/Akt/mTOR pathway to reverse the immunosuppression caused by sepsis. This study elucidates the potential mechanism of the immunotherapeutic effect of IFNγ in sepsis, providing a new target for the treatment of sepsis.

Citing Articles

Targeting sepsis through inflammation and oxidative metabolism.

Jacob S, Jacob S, Thoppil J World J Crit Care Med. 2025; 14(1):101499.

PMID: 40060738 PMC: 11671842. DOI: 10.5492/wjccm.v14.i1.101499.


Metabolic reprogramming in cancer and senescence.

Zhang Y, Tang J, Jiang C, Yi H, Guang S, Yin G MedComm (2020). 2025; 6(3):e70055.

PMID: 40046406 PMC: 11879902. DOI: 10.1002/mco2.70055.


A double-edged sword role of IFN-γ-producing iNKT cells in sepsis: Persistent suppression of Treg cell formation in an Nr4a1-dependent manner.

Qin Y, Qian Y, Liu S, Chen R iScience. 2024; 27(12):111462.

PMID: 39720538 PMC: 11667017. DOI: 10.1016/j.isci.2024.111462.


Immunotherapy in the context of sepsis-induced immunological dysregulation.

Wu Y, Wang L, Li Y, Cao Y, Wang M, Deng Z Front Immunol. 2024; 15:1391395.

PMID: 38835773 PMC: 11148279. DOI: 10.3389/fimmu.2024.1391395.


PD-1/PD-L1 axis induced host immunosuppression via PI3K/Akt/mTOR signalling pathway in piglets infected by Glaesserella Parasuis.

Li J, Liu S, Dong Q, Fu Y, Sun Y, Luo R BMC Vet Res. 2024; 20(1):141.

PMID: 38582846 PMC: 10998357. DOI: 10.1186/s12917-024-03993-1.


References
1.
Wijayasinghe Y, Bhansali M, Borkar M, Chaturbhuj G, Muntean B, Viola R . A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials. J Med Chem. 2022; 65(5):3706-3728. DOI: 10.1021/acs.jmedchem.1c01737. View

2.
Vlahos C, Matter W, Hui K, Brown R . A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994; 269(7):5241-8. View

3.
Buchman T, Simpson S, Sciarretta K, Finne K, Sowers N, Collier M . Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012-2018. Crit Care Med. 2020; 48(3):276-288. PMC: 7017943. DOI: 10.1097/CCM.0000000000004224. View

4.
Rhee C, Klompas M . Sepsis trends: increasing incidence and decreasing mortality, or changing denominator?. J Thorac Dis. 2020; 12(Suppl 1):S89-S100. PMC: 7024753. DOI: 10.21037/jtd.2019.12.51. View

5.
Cheng S, Quintin J, Cramer R, Shepardson K, Saeed S, Kumar V . mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014; 345(6204):1250684. PMC: 4226238. DOI: 10.1126/science.1250684. View